(NASDAQ: BCYC) Bicycle Therapeutics's forecast annual revenue growth rate of 18.14% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Bicycle Therapeutics's revenue in 2025 is $28,339,000.On average, 17 Wall Street analysts forecast BCYC's revenue for 2025 to be $2,002,373,686, with the lowest BCYC revenue forecast at $876,948,941, and the highest BCYC revenue forecast at $3,124,676,875. On average, 17 Wall Street analysts forecast BCYC's revenue for 2026 to be $2,001,680,007, with the lowest BCYC revenue forecast at $0, and the highest BCYC revenue forecast at $3,749,612,250.
In 2027, BCYC is forecast to generate $3,504,674,210 in revenue, with the lowest revenue forecast at $679,805,381 and the highest revenue forecast at $8,419,181,538.